top of page

PRODUCTS
- CANCER PRE-SCREENING
- BRCA GERMLINE
TECH & SCIENCE
CLINICAL TRIALS
- THE RAINBOW STUDY
- THE PINK STUDY
ABOUT
LET'S CONNECT
INVEST

All Posts
Technology
Early Detection
Screening
Innovation
Breath Samples
Research
People
Values
Goals
Process
VOC
AI
Expertise
Wellbeing
Team
Mission
Dogs
Non Invasive testing
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Privacy
Data
Regulation
Newsletter

All Posts

abstract illustration of SpotitEarly's cancer detection technology scalability

abstract illustration of SpotitEarly's cancer detection technology scalability

What are SpotitEarly’s Plans for Scaling its Cancer Detection Technology?

SpotitEarly Team

Dec 8, 20253 min read

CLIA Certification Explained: How SpotitEarly Ensures Trusted Cancer Detection

CLIA Certification Explained: How SpotitEarly Ensures Trusted Cancer Detection

CLIA Certification Explained: How SpotitEarly Ensures Trusted Cancer Detection

SpotitEarly Team

Nov 19, 20252 min read

abstract illustration of SpotitEarly's innovation in cancer diagnostics

abstract illustration of SpotitEarly's innovation in cancer diagnostics

The Future of Cancer Detection: SpotitEarly's Innovation Pipeline and Technological Breakthroughs

SpotitEarly Team

Oct 28, 20254 min read

Abstract illustration representing spotitearly innovation in the cancer detection industry

Abstract illustration representing spotitearly innovation in the cancer detection industry

Navigating the Cancer Detection Revolution: Industry Trends and How SpotitEarly is Leading the Change

SpotitEarly Team

Sep 24, 20254 min read

Protecting Patient Privacy: SpotitEarly’s Approach to Healthcare Data Security and HIPAA Compliance

Protecting Patient Privacy: SpotitEarly’s Approach to Healthcare Data Security and HIPAA Compliance

Protecting Patient Privacy: SpotitEarly’s Approach to Healthcare Data Security and HIPAA Compliance

SpotitEarly Team

Sep 17, 20253 min read

Abstract illustration comparing traditional cancer screening, liquid biopsies, and SpotitEarly’s breath test

Abstract illustration comparing traditional cancer screening, liquid biopsies, and SpotitEarly’s breath test

Cancer Screening Today: Traditional Tests, Liquid Biopsies, and SpotitEarly’s Breath-Based Breakthrough

Early Detection

SpotitEarly Team

Sep 10, 20255 min read

Illustration of dog working and detecting cancer at a SpotitEarly lab

Illustration of dog working and detecting cancer at a SpotitEarly lab

Inside the Training and Life of SpotitEarly’s Cancer Detection Dogs

SpotitEarly Team

Apr 18, 20255 min read

Illustration of SpotitEarly's revolutionary breath analysis for cancer detection

Illustration of SpotitEarly's revolutionary breath analysis for cancer detection

Why Breath Analysis Is Revolutionizing Early Cancer Detection

SpotitEarly Team

Apr 11, 20254 min read

Illustration of Dr. Len Lichtenfeld, CMO of SpotitEarly

Illustration of Dr. Len Lichtenfeld, CMO of SpotitEarly

Dr. Len Lichtenfeld Joins SpotitEarly as Chief Medical Officer to Advance Early Cancer Detection

SpotitEarly Team

Apr 4, 20253 min read

Illustration of LUCID, SpotitEarly's bio-hybrid cancer detection technology

Illustration of LUCID, SpotitEarly's bio-hybrid cancer detection technology

Inside LUCID: SpotitEarly’s Bio-Hybrid Platform Transforming Early Cancer Detection

SpotitEarly Team

Mar 28, 20253 min read

Illustration of SpotitEarly research and innovation

Illustration of SpotitEarly research and innovation

The Rainbow Study: Validating SpotitEarly’s Multi-Cancer Detection Method

SpotitEarly Team

Mar 21, 20254 min read

Illustration of SpotitEarly's transformative AI cancer detection technology

Illustration of SpotitEarly's transformative AI cancer detection technology

The transformative role of AI in SpotitEarly’s cancer screening process

SpotitEarly Team

Mar 14, 20253 min read

Illustration of SpotitEarly's Dogs ability to detect cancer

Illustration of SpotitEarly's Dogs ability to detect cancer

The Science Behind Dogs’ Ability to Detect Cancer Through Scent

SpotitEarly Team

Mar 7, 20254 min read

Illustration of SpotitEarly innovative early cancer detection work

Illustration of SpotitEarly innovative early cancer detection work

Discover SpotitEarly’s Groundbreaking Work in Early Cancer Detection

SpotitEarly Team

Feb 28, 20253 min read

Illustration of Udi Bobrovsky, SpotitEarly COO

Illustration of Udi Bobrovsky, SpotitEarly COO

The people behind healthcare innovation: Interview with Udi Bobrovsky, COO of SpotitEarly

SpotitEarly Team

Feb 21, 20251 min read

SpotitEarly at-home cancer screening test

SpotitEarly at-home cancer screening test

The journey of a SpotitEarly breath sample: From ordering to results

SpotitEarly Team

Feb 14, 20253 min read

How SpotitEarly Partners with Hospitals and Researchers to Drive Breakthrough Cancer Detection

How SpotitEarly Partners with Hospitals and Researchers to Drive Breakthrough Cancer Detection

How SpotitEarly Partners with Hospitals and Researchers to Drive Breakthrough Cancer Detection

SpotitEarly Team

Feb 7, 20253 min read

Meet the SpotitEarly Team: Innovators Behind Breath-Based Cancer Detection

Meet the SpotitEarly Team: Innovators Behind Breath-Based Cancer Detection

Meet the SpotitEarly Team: Innovators Behind Breath-Based Cancer Detection

SpotitEarly Team

Jan 31, 20256 min read

SpotitEarly’s Mission: Revolutionizing Global Cancer Detection Through Breath Analysis and AI

SpotitEarly’s Mission: Revolutionizing Global Cancer Detection Through Breath Analysis and AI

SpotitEarly’s Mission: Revolutionizing Global Cancer Detection Through Breath Analysis and AI

SpotitEarly Team

Jan 24, 20254 min read

DISCLAIMER

THE [OFFERING MATERIALS] MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM:

https://www.manhattanstreetcapital.com/offering-circular/36138

SAFE HARBOR STATEMENT

Matters discussed in this website contain forward-looking statements. When used in this update, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with our history of losses and our need to raise additional financing, the acceptance of our products and technology in the marketplace, our ability to demonstrate the commercial viability of our products and technology and our need to increase the size of our organization. Further information on the Company's risk factors is contained in the Company's Private Offering Memorandum. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason except as may be required under applicable law.

BIO-AI HYBRID PLATFORM
THE CANINE ADVANTAGE
BREATH SCIENCE
CANCER PRE-SCREENING
BRCA GERMLINE
THE RAINBOW STUDY
CANINE WELFARE
OUR STORY
TEAM & INVESTORS
LET'S CONNECT

ALL RIGHTS RESERVED,
SPOTITEARLY 2025

TERMS & CONDITIONS

CLIA registration: 99D2307137

USPTO patent pending: WO2023239834A1

hello@SpotitEarly.com

ALL RIGHTS RESERVED,
SPOTITEARLY 2026

SpotitEarly tests are not intended to replace current screening procedures, but rather to be used as an additional pre-screening layer to complement preventative protocols already in place.

The SpotitEarly tests have not been approved by the Food and Drug Administration (FDA) and are currently under development and validation.

Be the First to Know

Stay up to date with media features, clinical milestones, and where to find us next.

Email

PRODUCTS
- CANCER PRE-SCREENING
- BRCA GERMLINE
TECH & SCIENCE
CLINICAL TRIALS
- THE RAINBOW STUDY
- THE PINK STUDY
ABOUT
LET'S CONNECT
INVEST

bottom of page